Your account is not claimed yet. You can sign up with ORCID to claim your account.

Edoardo Francini

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Venues

Cancers

Journal of translational medicine

Prostate cancer and prostatic diseases

The Prostate

Università degli Studi di Firenze

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Firenze Mar 27o 2020

Italy

Assistant Professor :: Experimental and Clinical Medicine

Publications

Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q S Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, null null
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Journal of translational medicine 21 (1) (2023)
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q S Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, null null
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Journal of translational medicine 21 (1) (2023)
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q S Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, null null
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Journal of translational medicine 21 (1) (2023)
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q S Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, null null
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Journal of translational medicine 21 (1) (2023)
Edoardo Francini, Giuseppe Nicolò Fanelli, Filippo Pederzoli, Sandor Spisak, Erika Minonne, Massimiliano Raffo, Hubert Pakula, Viktoria Tisza, Cristian Scatena, Antonio Giuseppe Naccarato, Massimo Loda, Pier Vitale Nuzzo
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine. Cancers 14 (18) (2022)
Valerio Gristina, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono, Alessandro Perez, Delia Sardo, Sara Inguglia, Federica Iacono, Sofia Cutaia, Tancredi Didier Bazan Russo, Edoardo Francini, Antonio Russo, Giuseppe Badalamenti, Antonio Russo, Antonio Galvano, Viviana Bazan
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers 14 (23) (2022)
Valerio Gristina, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono, Alessandro Perez, Delia Sardo, Sara Inguglia, Federica Iacono, Sofia Cutaia, Tancredi Didier Bazan Russo, Edoardo Francini, Antonio Russo, Giuseppe Badalamenti, Antonio Russo, Antonio Galvano, Viviana Bazan
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers 14 (23) (2022)
Valerio Gristina, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono, Alessandro Perez, Delia Sardo, Sara Inguglia, Federica Iacono, Sofia Cutaia, Tancredi Didier Bazan Russo, Edoardo Francini, Antonio Russo, Giuseppe Badalamenti, Antonio Russo, Antonio Galvano, Viviana Bazan
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers 14 (23) (2022)
Edoardo Francini, Fang-Shu Ou, Justin Rhoades, Eric G Wolfe, Edward P O'Connor, Gavin Ha, Gregory Gydush, Kaitlin M Kelleher, Rupal S Bhatt, Steven P Balk, Christopher J Sweeney, Viktor A Adalsteinsson, Mary-Ellen Taplin, Atish D Choudhury
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers 13 (16) (2021)
Bradley Alexander McGregor, Li Zhang, Kathryn P Gray, Grace Shaw, Carolyn Evan, Edoardo Francini, Christopher Sweeney
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate cancer and prostatic diseases 24 (2) (2020)
Edoardo Francini, Kathryn P Gray, Grace K Shaw, Carolyn P Evan, Anis A Hamid, Caitlin E Perry, Philip W Kantoff, Mary-Ellen Taplin, Christopher J Sweeney
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate cancer and prostatic diseases 22 (3) (2019)
Edoardo Francini, Kathryn P Gray, Wanling Xie, Grace K Shaw, Loana Valença, Brandon Bernard, Laurence Albiges, Lauren C Harshman, Philip W Kantoff, Mary-Ellen Taplin, Cristopher J Sweeney
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). The Prostate 78 (12) (2018)

Edoardo Francini.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Edoardo Francini